glp-1 agonists with cardiovascular benefit in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies The Benefits of GLP-1 Therapy:

Study variability Many of the studies assessed were of relatively low quality (case studies or small study groups) and were therefore underpowered, and potentially had selection biases due to unmeasured confounders

What happens if I stop taking GLP-1 medication

Its all about explaining that different people have different responses, said Dr

Front Endocrinol (Lausanne) 12:645566 Zhang Y et al (2022) Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

First, the FDA has uncovered many cases where the drug ingredient claimed on a label was not what was actually in the product